Business Wire
Precision BioSciences Receives $7.5M in Proceeds from TG Therapeutics for Azer-cel Clinical Milestone in Multiple Sclerosis
📈
AI Sentiment
Highly Positive
9/10
- Home
- DTIL
as of 03-09-2026 3:58pm EST
$4.73
+$0.13
+2.83%
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | DURHAM |
| Market Cap: | 97.7M | IPO Year: | 2019 |
| Target Price: | $60.00 | AVG Volume (30 days): | 158.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -6.14 | EPS Growth: | 106.52 |
| 52 Week Low/High: | $3.53 - $8.82 | Next Earning Date: | 03-31-2026 |
| Revenue: | $1,070,000,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | -86.43% | Revenue Growth (next year): | 34.30% |
| P/E Ratio: | -0.75 | Index: | N/A |
| Free Cash Flow: | -58695000.0 | FCF Growth: | N/A |
Stock Insider Trading Activity of Precision BioSciences Inc. (DTIL)
Scimeca Dario
Sell
General Counsel and Secretary
DTIL Feb 18, 2026
Avg Cost/Share
$3.84
Shares
4,925
Total Value
$18,912.00
Owned After
56,457
SEC Form 4
SMITH J. JEFFERSON
Sell
Chief Research Officer
DTIL Feb 18, 2026
Avg Cost/Share
$3.84
Shares
4,925
Total Value
$18,912.00
Owned After
121,926
SEC Form 4
Kelly John Alexander
Sell
Chief Financial Officer
DTIL Feb 18, 2026
Avg Cost/Share
$3.84
Shares
8,149
Total Value
$31,292.16
Owned After
125,883
SEC Form 4
Amoroso Michael
Sell
President and CEO
DTIL Feb 18, 2026
Avg Cost/Share
$3.84
Shares
20,559
Total Value
$78,946.56
Owned After
243,392
SEC Form 4
Amoroso Michael
Sell
President and CEO
DTIL Jan 22, 2026
Avg Cost/Share
$4.17
Shares
34,799
Total Value
$145,111.83
Owned After
243,392
SEC Form 4
Scimeca Dario
Sell
General Counsel and Secretary
DTIL Jan 21, 2026
Avg Cost/Share
$4.03
Shares
8,854
Total Value
$35,681.62
Owned After
56,457
SEC Form 4
SMITH J. JEFFERSON
Sell
Chief Research Officer
DTIL Jan 21, 2026
Avg Cost/Share
$4.03
Shares
10,200
Total Value
$41,106.00
Owned After
121,926
SEC Form 4
Kelly John Alexander
Sell
Chief Financial Officer
DTIL Jan 21, 2026
Avg Cost/Share
$4.03
Shares
15,213
Total Value
$61,308.39
Owned After
125,883
SEC Form 4
Germano Geno J
Buy
Director
DTIL Dec 16, 2025
Avg Cost/Share
$4.72
Shares
3,000
Total Value
$14,160.00
Owned After
23,883
SEC Form 4
Frankel Stanley
Buy
Director
DTIL Dec 16, 2025
Avg Cost/Share
$4.70
Shares
2,700
Total Value
$12,690.00
Owned After
19,478
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Scimeca Dario | DTIL | General Counsel and Secretary | Feb 18, 2026 | Sell | $3.84 | 4,925 | $18,912.00 | 56,457 | |
| SMITH J. JEFFERSON | DTIL | Chief Research Officer | Feb 18, 2026 | Sell | $3.84 | 4,925 | $18,912.00 | 121,926 | |
| Kelly John Alexander | DTIL | Chief Financial Officer | Feb 18, 2026 | Sell | $3.84 | 8,149 | $31,292.16 | 125,883 | |
| Amoroso Michael | DTIL | President and CEO | Feb 18, 2026 | Sell | $3.84 | 20,559 | $78,946.56 | 243,392 | |
| Amoroso Michael | DTIL | President and CEO | Jan 22, 2026 | Sell | $4.17 | 34,799 | $145,111.83 | 243,392 | |
| Scimeca Dario | DTIL | General Counsel and Secretary | Jan 21, 2026 | Sell | $4.03 | 8,854 | $35,681.62 | 56,457 | |
| SMITH J. JEFFERSON | DTIL | Chief Research Officer | Jan 21, 2026 | Sell | $4.03 | 10,200 | $41,106.00 | 121,926 | |
| Kelly John Alexander | DTIL | Chief Financial Officer | Jan 21, 2026 | Sell | $4.03 | 15,213 | $61,308.39 | 125,883 | |
| Germano Geno J | DTIL | Director | Dec 16, 2025 | Buy | $4.72 | 3,000 | $14,160.00 | 23,883 | |
| Frankel Stanley | DTIL | Director | Dec 16, 2025 | Buy | $4.70 | 2,700 | $12,690.00 | 19,478 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K SELL Jan 13, 2026 · 100% conf.
2025
Q4
Q4 2025 Earnings
8-K SELLJan 13, 2026 · 100% conf.
AI Prediction SELL
1D
-3.65%
$3.96
Act: +0.49%
5D
-9.49%
$3.72
Act: -2.43%
20D
-8.99%
$3.74
Act: -0.97%
Price: $4.11 Prob +5D: 0% AUC: 1.000
0001628280-26-001955
dtil-202601120001357874FALSE00013578742026-01-122026-01-12
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2026
Precision BioSciences, Inc. (Exact name of Registrant as Specified in Its Charter)
Delaware001-3884120-4206017 (State or Other Jurisdiction of Incorporation)(Commission File Number)(IRS Employer Identification No.)
302 East Pettigrew St. Suite A-100
Durham, North Carolina 27701 (Address of Principal Executive Offices)(Zip Code)
Registrant’s Telephone Number, Including Area Code: 919 314-5512 (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, par value $0.000005 per shareDTILThe Nasdaq Capital Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition. Although it has not finalized its full financial results for the year ended December 31, 2025, Precision BioSciences, Inc. (the “Company”) expects to report that it had approximately $137 million in cash, cash equivalents, and restricted cash as of December 31, 2025. This estimate is unaudited and preliminary and does not present all information necessary for an understanding of the Company’s financial condition as of December 31, 2025, or its results of operations for the year ended December 31, 2025. The audit of the Company’s financial statements for the year ended December 31, 2025, by the Company’s independent registered public accounting firm is ongoing and could result in changes to the information set forth above. The Company expects that existing cash and cash equivalents, potential near-term consideration to be received from licensees, continued fiscal and operating discipline, and availability of the Company’s at-the-market facility will extend the Company’s cash runway through 2028.
Item 7.01 Regulation FD Disclosure On January 12, 2026, the Company issued a press release to set strategic priorities for 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The Company has also updated its corporate deck, which is available in the “Investors” portion of the Company’s website at https://investor.precisionbiosciences.com. Pursuant to General Instruction B.2 of Current Report on Form 8-K, the information contained in, or incorporated by reference into, Item 2.02 and this Item 7.01 (including the Press Release attached hereto as Exhibit 99.1) of this Current Report on Form 8-K is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any registration statement or other filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing. Item 8.01 Other Events On January 12, 2026, the Company announced additional biopsy data in the ELIMINATE-B trial for PBGENE-HBV is expected in the first half of 2026. In addition, the Company expects to complete dosing Cohorts 3, 4, and 5 and choose the optimal dosing regimen to achieve the goal of stopping nucleos(t)ide analog treatment and begin Part 2 expansion of the trial. Pending clearance of the investigational new drug application, the FUNCTION-DMD Phase 1/2 clinical trial in D
2025 Q3 Q3 2025 Earnings
8-K Nov 3, 2025
2025
Q3
Q3 2025 Earnings
8-KNov 3, 2025
0001628280-25-047920
dtil-202511030001357874FALSE00013578742025-11-032025-11-03
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2025
Precision BioSciences, Inc. (Exact name of Registrant as Specified in Its Charter)
Delaware001-3884120-4206017 (State or Other Jurisdiction of Incorporation)(Commission File Number)(IRS Employer Identification No.)
302 East Pettigrew St. Suite A-100
Durham, North Carolina 27701 (Address of Principal Executive Offices)(Zip Code)
Registrant’s Telephone Number, Including Area Code: 919 314-5512 (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, par value $0.000005 per shareDTILThe Nasdaq Capital Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition. On November 3, 2025, Precision BioSciences, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2025. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits. (d)Exhibits
Exhibit No.Description
99.1Press release of Precision BioSciences, Inc. dated November 3, 2025.
104Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
PRECISION BIOSCIENCES, INC.
Date:November 3, 2025By:/s/ John Alexander Kelly John Alexander Kelly Chief Financial Officer
2025 Q2 Q2 2025 Earnings
8-K Aug 7, 2025
2025
Q2
Q2 2025 Earnings
8-KAug 7, 2025
0001628280-25-038592
dtil-202508070001357874FALSE00013578742025-08-072025-08-07
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2025
Precision BioSciences, Inc. (Exact name of Registrant as Specified in Its Charter)
Delaware001-3884120-4206017 (State or Other Jurisdiction of Incorporation)(Commission File Number)(IRS Employer Identification No.)
302 East Pettigrew St. Suite A-100
Durham, North Carolina 27701 (Address of Principal Executive Offices)(Zip Code)
Registrant’s Telephone Number, Including Area Code: 919 314-5512 (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, par value $0.000005 per shareDTILThe Nasdaq Capital Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition. On August 7, 2025, Precision BioSciences, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2025. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits. (d)Exhibits
Exhibit No.Description
99.1Press release of Precision BioSciences, Inc. dated August 7, 2025.
104Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
PRECISION BIOSCIENCES, INC.
Date:August 7, 2025By:/s/ John Alexander Kelly John Alexander Kelly Chief Financial Officer
Latest Precision BioSciences Inc. News
DTIL Breaking Stock News: Dive into DTIL Ticker-Specific Updates for Smart Investing
Compare DTIL vs Leading Stocks
See how DTIL stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "DTIL Precision BioSciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.